Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treatments also allow stabilization of clinical symptomatology. However, validated treatment guidelines for RCC patients with brain metastases are not yet available on account of the frequent exclusion of such patients from clinical trials. Moreover, limited data about the sequential use of three therapies, changing the class of agent, have been published up to now. Case Report. We report the case of a patient with metastatic RCC who developed disease progression after sunitinib and everolimus as first-line and second-line therapy, respectively. Thus, he underwent a multimodality treatment with pazopanib, as third-line therapy, to control systemic disease and radiosurgery directed on the new brain metastasis. To date, the patient is still receiving pazopanib, with progression-free survival and overall survival of 43 and 103 months, respectively. Conclusion. In a context characterized by different emerging options, with no general consensus on the optimal treatment strategy, the use of pazopanib in pretreated patients could be a suitable choice. PMID: 26798533 PMCID: PMC4698998 DOI: 10.1155/2015/629046

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma / Roberto, Michela; Bassanelli, Maria; Iannicelli, Elsa; Giacinti, Silvana; D'Antonio, Chiara; Aschelter, Anna Maria; Marchetti, Paolo. - In: CASE REPORTS IN ONCOLOGICAL MEDICINE. - ISSN 2090-6706. - STAMPA. - 2015:(2015), pp. 1-4. [10.1155/2015/629046]

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma

ROBERTO, MICHELA;BASSANELLI, MARIA;IANNICELLI, Elsa;GIACINTI, SILVANA;D'ANTONIO, CHIARA;MARCHETTI, PAOLO
2015

Abstract

Background. Renal cell carcinoma accounts for about 2-3% of all malignant tumors. The prevalence of brain metastases from RCC is less than 20% of cases. Traditionally, whole brain radiotherapy as well as the latest stereotactic radiosurgery improves both survival and local tumor control. These treatments also allow stabilization of clinical symptomatology. However, validated treatment guidelines for RCC patients with brain metastases are not yet available on account of the frequent exclusion of such patients from clinical trials. Moreover, limited data about the sequential use of three therapies, changing the class of agent, have been published up to now. Case Report. We report the case of a patient with metastatic RCC who developed disease progression after sunitinib and everolimus as first-line and second-line therapy, respectively. Thus, he underwent a multimodality treatment with pazopanib, as third-line therapy, to control systemic disease and radiosurgery directed on the new brain metastasis. To date, the patient is still receiving pazopanib, with progression-free survival and overall survival of 43 and 103 months, respectively. Conclusion. In a context characterized by different emerging options, with no general consensus on the optimal treatment strategy, the use of pazopanib in pretreated patients could be a suitable choice. PMID: 26798533 PMCID: PMC4698998 DOI: 10.1155/2015/629046
tyrosine kinase inhibitors; prognostic-factors; brain metastasis; targeted therapies; phase-3 trial; everolimus; sorafenib; survival
01 Pubblicazione su rivista::01a Articolo in rivista
Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma / Roberto, Michela; Bassanelli, Maria; Iannicelli, Elsa; Giacinti, Silvana; D'Antonio, Chiara; Aschelter, Anna Maria; Marchetti, Paolo. - In: CASE REPORTS IN ONCOLOGICAL MEDICINE. - ISSN 2090-6706. - STAMPA. - 2015:(2015), pp. 1-4. [10.1155/2015/629046]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/906971
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 4
social impact